| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Genmab A/S: Capital Increase in Genmab as a Result of Employee Warrant Exercise | 3 | GlobeNewswire (USA) | ||
| Mo | Genmab A/S: Transactions in Connection with Share Buy-back Program | 3 | GlobeNewswire (USA) | ||
| Fr | Earnings call: Genmab reports strong Q1 growth, plans ProfoundBio acquisition | 21 | Investing.com | ||
| 02.05. | Genmab A/S reports results for the quarter ended in January - Earnings Summary | 11 | Reuters | ||
| 02.05. | GENMAB A/S - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 02.05. | Genmab A/S: Genmab Announces Financial Results for the First Quarter of 2024 | 159 | GlobeNewswire (Europe) | May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental... ► Artikel lesen | |
| 30.04. | Pfizer and Genmab Receive FDA Approval for Cervical Cancer Drug | 7 | Baystreet.ca | ||
| 30.04. | Pfizer and Genmab's Tivdak wins full FDA approval for cervical cancer | 3 | Pharmaceutical Technology | ||
| 30.04. | Decoding 9 Analyst Evaluations For Genmab | 3 | Benzinga.com | ||
| 30.04. | Pfizer/Genmab's Tivdak granted full FDA approval for recurrent or metastatic cervical cancer | 6 | PMLiVE | ||
| 30.04. | Genmab and Pfizer's TIVDAK sBLA secures full FDA approval | 3 | Pharmaceutical Business Review | ||
| 30.04. | Pfizer,Genmab: FDA Grants Full Approval For TIVDAK To Treat Recurrent Or Metastatic Cervical Cancer | 602 | AFX News | NEW YORK CITY (dpa-AFX) - The U.S. Food and Drug Administration approved the supplemental Biologics License
Application or sBLA granting full approval for TIVDAK (tisotumab vedotin-tftv) for... ► Artikel lesen | |
| 30.04. | Genmab A/S: TIVDAK (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer | 363 | Business Wire | Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapy TIVDAK is the first antibody-drug conjugate... ► Artikel lesen | |
| 29.04. | Genmab A/S: Transactions in Connection with Share Buy-back Program Genmab | 4 | GlobeNewswire (USA) | ||
| 22.04. | GENMAB A/S - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 22.04. | Genmab A/S: Transactions in Connection with Share Buy-back Program Genmab | 8 | GlobeNewswire (USA) | ||
| 16.04. | Genmab's Q1 Darzalex Sales By Johnson & Johnson Reach $2.692 Bln | 566 | AFX News | NEW BRUNSWICK (dpa-AFX) - Genmab A/S (GMAB), a Danish biotechnology firm, announced on Tuesday that the first-quarter sales of Darzalex, Daratumumab, have totaled $2.692 billion, as updated... ► Artikel lesen | |
| 16.04. | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2024 | 471 | GlobeNewswire (Europe) | Company Announcement Net sales of DARZALEX® in the first quarter of 2024 totaled USD 2,692 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN,... ► Artikel lesen | |
| 15.04. | GENMAB A/S - 6-K, Report of foreign issuer | 609 | SEC Filings | ||
| 15.04. | Genmab A/S: Transactions in Connection with Share Buy-back Program Genmab | 556 | GlobeNewswire (USA) |
Seite:
1 2 3 4 5 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 3.166 |
| MERCEDES-BENZ | 2.597 |
| NEL | 2.563 |
| SIEMENS ENERGY | 2.364 |
| PLUG POWER | 2.215 |
| BAYER | 2.043 |
| TUI | 1.985 |
| ALLIANZ | 1.806 |
| PALANTIR TECHNOLOGIES | 1.803 |
| BYD | 1.498 |
| NVIDIA | 1.489 |
| DEUTSCHE BANK | 1.392 |
| DEUTSCHE LUFTHANSA | 1.292 |
| INFINEON | 1.104 |
| RWE | 1.103 |
| VARTA | 1.065 |
| PUMA | 1.061 |
| VOLKSWAGEN | 1.026 |
| SUPER MICRO COMPUTER | 1.005 |
| RENK GROUP | 1.003 |
| RHEINMETALL | 991 |
| TESLA | 988 |
| AIXTRON SE | 932 |
| BORUSSIA DORTMUND | 908 |
| SMA SOLAR | 905 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
